MX2022007929A - Coagonistas de triazol grapados de los receptores de glucagon y glp-1. - Google Patents

Coagonistas de triazol grapados de los receptores de glucagon y glp-1.

Info

Publication number
MX2022007929A
MX2022007929A MX2022007929A MX2022007929A MX2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A
Authority
MX
Mexico
Prior art keywords
glp
glucagon
agonists
receptors
stapled
Prior art date
Application number
MX2022007929A
Other languages
English (en)
Inventor
Songnian Lin
Anandan Palani
Qiaolin Deng
Federica Orvieto
Elisabetta Bianchi
Antonello Pessi
Tomi K Sawyer
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022007929A publication Critical patent/MX2022007929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los péptidos grapados de la presente invención, y las sales farmacéuticamente aceptables de los mismos, son los coagonistas de los receptores de glucagon y GLP-1, y pueden ser útiles en el tratamiento, la prevención y la supresión de las enfermedades mediadas por el receptor de glucagon y el receptor de GLP-1, los que incluyen, pero no se limitan a, los trastornos metabólicos tales como la diabetes, la enfermedad del hígado graso no alcohólico (NAFLD, por sus siglas en inglés), la esteatohepatitis no alcohólica (NASH, por sus siglas en inglés) y la obesidad.
MX2022007929A 2019-12-23 2020-12-18 Coagonistas de triazol grapados de los receptores de glucagon y glp-1. MX2022007929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19425098.1A EP3842061A1 (en) 2019-12-23 2019-12-23 Stapled triazole co-agonists of the glucagon and glp-1 receptors
PCT/US2020/065796 WO2021133644A1 (en) 2019-12-23 2020-12-18 Stapled triazole co-agonists of the glucagon and glp-1 receptors

Publications (1)

Publication Number Publication Date
MX2022007929A true MX2022007929A (es) 2022-09-29

Family

ID=69326342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007929A MX2022007929A (es) 2019-12-23 2020-12-18 Coagonistas de triazol grapados de los receptores de glucagon y glp-1.

Country Status (10)

Country Link
US (1) US20230063794A1 (es)
EP (2) EP3842061A1 (es)
JP (1) JP2023508349A (es)
KR (1) KR20220119475A (es)
CN (1) CN115226391A (es)
AU (1) AU2020412677A1 (es)
BR (1) BR112022012499A2 (es)
CA (1) CA3162800A1 (es)
MX (1) MX2022007929A (es)
WO (1) WO2021133644A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310838A (en) * 2021-08-27 2024-04-01 Univ Yale Molecular assemblies of extracellular proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
JP4181408B2 (ja) 2001-01-30 2008-11-12 メルク エンド カムパニー インコーポレーテッド 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
MXPA05002303A (es) 2002-08-29 2005-06-08 Merck & Co Inc Indoles con actividad antidiabetica.
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004066963A2 (en) 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US8546326B2 (en) * 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
US8175737B2 (en) 2006-07-19 2012-05-08 Freescale Semiconductor, Inc. Method and apparatus for designing and integrated circuit
WO2009000087A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
KR101404781B1 (ko) 2007-06-28 2014-06-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제조 방법
JP2010533712A (ja) 2007-07-19 2010-10-28 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物としてのベータカルボリン誘導体
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
CA2935026C (en) * 2014-01-15 2018-11-13 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated prolactin-releasing peptides for lowering blood glucose
CA2964379C (en) 2014-10-24 2023-08-15 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors
WO2017189342A1 (en) * 2016-04-26 2017-11-02 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
EP3700550A4 (en) 2017-09-25 2022-02-23 Merck Sharp & Dohme Corp. LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物

Also Published As

Publication number Publication date
EP4081243A1 (en) 2022-11-02
EP3842061A1 (en) 2021-06-30
EP4081243A4 (en) 2024-01-10
WO2021133644A1 (en) 2021-07-01
CN115226391A (zh) 2022-10-21
US20230063794A1 (en) 2023-03-02
AU2020412677A1 (en) 2022-07-14
JP2023508349A (ja) 2023-03-02
BR112022012499A2 (pt) 2022-09-06
KR20220119475A (ko) 2022-08-29
CA3162800A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
PH12017500761A1 (en) Co-agonists of glucagon and glp-1 receptors
PH12020551025A1 (en) Incretin analogs and uses thereof
PH12020551024A1 (en) Incretin analogs and uses thereof
PH12021551165A1 (en) Glp-1r agonists and uses thereof
PH12017502359B1 (en) Glucagon and glp-1 co-agonist compounds
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2015010935A (es) Compuestos biciclicos antidiabeticos.
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MX2016015182A (es) Compuestos triciclicos antidiabeticos.
PH12019550226A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EA202091464A1 (ru) Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications
MX2022007666A (es) Analogos de incretina y sus usos.
MX2022007928A (es) Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1.
MX2022007926A (es) Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.
MX2022013230A (es) Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.
MX2022000388A (es) Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4.
WO2015051234A3 (en) Tweak antagonists for treating lupus nephritis and muscle atrophy
TH1701002228A (th) อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์